**Background of PRELP Antibody**
PRELP (Proline/Arginine-Rich End Leucine-Rich Repeat Protein) is a small leucine-rich repeat proteoglycan (SLRP) predominantly found in connective tissues, including cartilage, bone, and skin. It plays a critical role in maintaining extracellular matrix (ECM) stability by interacting with collagen fibrils and other ECM components through its leucine-rich repeat domains. PRELP’s N-terminal region, rich in proline and arginine, mediates binding to glycosaminoglycans and basement membrane components, contributing to tissue organization and mechanical resilience.
Research highlights PRELP’s involvement in regulating innate immunity and inflammation. It inhibits the complement system by binding to complement C1q, modulating immune responses in tissues. Dysregulation of PRELP is linked to pathologies like osteoarthritis, rheumatoid arthritis, and fibrosis, underscoring its role in ECM homeostasis and disease.
PRELP antibodies are essential tools for detecting and quantifying PRELP expression in tissues or biological fluids. They enable studies on PRELP’s localization, function, and interaction partners via techniques like immunohistochemistry, Western blotting, and ELISA. These antibodies also aid in exploring PRELP’s therapeutic potential, such as targeting ECM remodeling in degenerative diseases or modulating immune pathways. Commercial PRELP antibodies are typically validated for specificity across human, mouse, or rat samples, supporting translational research in connective tissue disorders and inflammation.